| Literature DB >> 33327871 |
Ziyan Zhou1,2, Chang Liu3, Kang Liu1,2, Meixin Lv3, Baibei Li3, Zhenrui Lan3, Wei Chen1,2, Min Kang1,2.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is the sixth most prevalent malignancy worldwide, with high incidence and poor survival rates. Increased expression of microRNA-205-5p (miR-205-5p) may influence the outcomes of HNSCC, but the identities of miR-205-5p target genes and the potential signaling pathways related to HNSCC remain unclear. RT-qPCR was used to detect the expression levels of miR-205-5p in the plasma of patients with HNSCC. We also performed a meta-analysis using data from relevant literature, and the Gene Expression Omnibus (GEO) and the Cancer Genome Atlas (TCGA) databases to evaluate the expression level of miR-205-5p in HNSCC. Next, we predicted the potential miR-205-5p target genes in HNSCC. We also used Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) for enrichment analyses adapted to investigate the dynamics and possible mechanisms of miR-205-5p in HNSCC. Lastly, we predicted the potential miR-205-5p target genes by evaluating their expression level and using Spearman analysis. Expression of miR-205-5p was higher in HNSCC tissues compared to normal unafflicted tissue samples (P < 0.05), and the corresponding summary receiver operating characteristic (sROC) was 0.82.The pooled sensitivity, specificity, PLR, NLR, and DOR values were 0.78 (95% CI: 0.75-0.81), 0.67 (95% CI: 0.60-0.73), 2.34 (95% CI: 1.45-3.76), 0.34 (95% CI: 0.19-0.60), and 8.16 (95% CI: 4.01-16.64), respectively. Based on GO and KEGG analyses, we found that miR-205-5p was correlated with the progression of HNSCC through association with signaling pathways, including the drug metabolism-cytochrome P450 pathway. Analysis of the target genes revealed that flavin-containing monooxygenase isoform 2 (FMO2) and alcohol dehydrogenase 1B (ADH1B) may be important targets of miR-205-5p. In summary, miR-205-5p may have a significant role in the prognosis of HNSCC and may serve as a potential biomarker in HNSCC.Entities:
Keywords: gene; head and neck squamous cell carcinoma; microRNA-205-5p; molecular mechanism; signaling pathway
Year: 2020 PMID: 33327871 PMCID: PMC7750893 DOI: 10.1177/1533033820980110
Source DB: PubMed Journal: Technol Cancer Res Treat ISSN: 1533-0338
Figure 1.Levels of miR-205-5p in HNSCC and NC plasma samples. Compared with the control group (n = 12), miR-205-5p was significantly upregulated in HNSCC plasma (n = 15) (p < 0.01).
Figure 2.Flow diagram for literature search and quality screening.
Features of Included Data.
| Researcher | Year | Country | Cancer/normal | Methods | Sample |
|---|---|---|---|---|---|
| GSE11163 | 2012 | USA | 16/5 | qPCR | Tissue |
| GSE32177 | 2018 | USA | 15/15 | qPCR | Tissue |
| GSE34496 | 2017 | USA | 44/25 | qPCR | Tissue |
| GSE45238 | 2019 | USA | 40/40 | qPCR | Tissue |
| GSE75630 | 2016 | USA | 28/18 | qPCR | Tissue |
| GSE103931 | 2018 | USA | 30/19 | qPCR | Tissue |
| GSE107591 | 2018 | USA | 24/23 | qPCR | Tissue |
| Cao et al | 2012 | China | 48/48 | qPCR | Tissue |
| TCGA | 2019 | USA | 523/44 | qPCR | Tissue |
Figure 3.Scatter diagrams for levels of expression of miR-205-5p in HNSCC patients. A. GSE11163; B.GSE31277; C.GSE34496; D.GSE45238; E.GSE75630; F.GSE103931; G.GSE107591; H.PMID22605671; I.TCGA.
Figure 4.Comparisons of the levels of expression of miR-205-5p between HNSCC and normal tissues evaluated by forest plots based on data from published literature, and the TCGA and GEO database datasets. A. Fixed-effect model of Forest plots; B. Random-effect model of Forest plots.
Figure 5.Bias analysis. Funnel plot with pseudo 95% confidence limits for the assessment of publication biases in meta-analysis.
Figure 6.The performance of predictive role of miR-205-5p in HNSCC afflicted samples. A. Sensitivity; B. Specificity; C. Positive Likelihood Ratio (Positive LR); D. Negative Likelihood Ratio (Negative LR); E. Diagnostic Odds Ratio (DOR).
Figure 7.Receiver operating characteristic (ROC) curves from each study indicating measures of diagnostic accuracy of miR-205-5p in HNSCC afflicted samples.
Figure 8.Summary receiver operating characteristic (sROC) curve for evaluation of diagnostic accuracy of miR-205-5p in HNSCC afflicted samples.
The Correlation Between miR-205-5p Expression and Clinical Features From TCGA Data.
| Clinicopathological features | Terms | n | Mean ± SD | p-value |
|---|---|---|---|---|
| Unpaired tissue | Normal | 44 | 12.13 ± 1.61 | <0.0001 |
| HNSCC | 523 | 13.68 ± 0.05 | ||
| Gender | Male | 383 | 13.66 ± 1.13 | 0.657 |
| Female | 141 | 13.71 ± 0.89 | ||
| Age | <60 | 234 | 13.78 ± 1.02 | 0.039 |
| ≥60 | 290 | 13.59 ± 1.10 | ||
| Lymphovascular invasion | No | 232 | 13.69 ± 0.07 | 0.196 |
| Yes | 122 | 13.53 ± 1.21 | ||
| Pathologic grade | G1-G2 | 371 | 13.69 ± 0.05 | 0.691 |
| G3-G4 | 132 | 13.64 ± 1.34 | ||
| Clinical grade |
| 112 | 13.61 ± 1.08 | 0.463 |
|
| 412 | 13.70 ± 1.06 | ||
| T stage | T1-T2 | 188 | 13.66 ± 1.15 | 0.900 |
| T3-T4 | 324 | 13.67 ± 1.02 | ||
| N stage | N0 | 246 | 13.67 ± 0.98 | 0.859 |
| N1-N3 | 259 | 13.66 ± 1.15 | ||
| M stage | M0 | 498 | 13.67 ± 1.06 | 0.100 |
| M1 | 6 | 14.38 ± 0.46 | ||
| Alcohol | No | 164 | 13.69 ± 0.10 | 0.858 |
| Yes | 350 | 13.67 ± 0.10 |
Notes: SD, standard deviation; HNSCC, Head and neck squamous cell carcinoma; T stage, size or direct extent of the primary tumor; N stage, range of spread to regional lymph nodes; M stage, presence of distant metastasis.
Figure 9.VENNY diagram showing the intersection of predicted miR-205-5p target genes.
The Promising Target Genes of miR-205 in HNSCC With TCGA and MiRWalk.
| Sources of genes | Genes |
|---|---|
| TCGA and MiRWalk | LDB3, CYP3A5, MUC20, SERPINB11, ALDH1L1, ALOX12 |
| UGT1A7, GABRP, FAM3D, GBP6, HOPX, PAX9, CXCR2, ATP13A4, NCCRP1, S100A1, MUC4, PPL | |
| SH3BGRL2, LTF, CRISP3, LYNX1, GPX3, KRT23, PADI1, UPK1A, ENDOU, GPD1, HLF, FMO2, KLK12, KRT78 | |
| PDK4, CGNL1, CYP4F22, AQP3, IL1RN, CA3, TNNI1 | |
| RORC, HSPB7, EYA2, SCIN, PIGR, ATP2A1, DES, TMPRSS2, ATP6V0A4, ADH1B, PPP1R3C | |
| PI16, MYOZ1, XIRP2, MYZAP, GCNT3, PPP1R1A, TGM1 |
Figure 10.Enrichment analysis of GO and KEGG pathways of miR-205-5p target genes. A. Gene ontology (GO) of candidate genes; B. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis.
Predictive Genes of miR-205 by GO Analysis.
| GO ID | GO term | Counts(%) | Gene symbol | P-value |
|---|---|---|---|---|
| Biological process | ||||
| GO:0008016 | regulation of heart contraction | 4 | DES, HSPB7, HOPX, S100A1 | 1.18E-04 |
| GO:0007588 | excretion | 3 | UGT1A7, ATP6V0A4, AQP3 | 0.005844767 |
| GO:0016266 | O-glycan processing | 3 | GCNT3, MUC20, MUC4 | 0.014845857 |
| GO:0006805 | xenobiotic metabolic process | 3 | CYP3A5, FMO2, RORC | 0.024314658 |
| GO:0034220 | ion transmembrane transport | 4 | ATP2A1, ATP6V0A4, AQP3, ATP13A4 | 0.027210698 |
| GO:0006942 | regulation of striated muscle contraction | 2 | ATP2A1, TNNI1 | 0.027534149 |
| GO:0006885 | regulation of pH | 2 | PDK4, ATP6V0A4 | 0.048434249 |
| GO:0010906 | regulation of glucose metabolic process | 2 | PDK4, RORC | 0.065997490 |
| GO:0042476 | odontogenesis | 2 | PAX9, AQP3 | 0.080390330 |
| GO:0017144 | drug metabolic process | 2 | UGT1A7, FMO2 | 0.080390330 |
| GO:0005977 | glycogen metabolic process | 2 | PPP1R3C, PPP1R1A | 0.086086359 |
| GO:0006730 | one-carbon metabolic process | 2 | ALDH1L1, CA3 | 0.088921383 |
| Cellular component | ||||
| GO:0070062 | extracellular exosome | 25 | GPD1, TMPRSS2, CRISP3, GBP6, GCNT3, ALDH1L1, IL1RN, PIGR, PADI1, MUC4, DES, LYNX1, NCCRP1, UPK1A, PPL, SCIN, KRT78, TGM1, GPX3, KLK12, SH3BGRL2, LTF, ATP6V0A4, PI16, ALOX12 | 8.32E-07 |
| GO:0030018 | Z disc | 6 | DES, XIRP2, MYZAP, LDB3, MYOZ1, S100A1 | 3.07E-05 |
| GO:0005615 | extracellular space | 11 | CRISP3, PPP1R1A, GPX3, ENDOU, KRT78, IL1RN, KLK12, LTF, SERPINB11, PIGR, MUC4 | 0.007351259 |
| GO:0031090 | organelle membrane | 3 | CYP3A5, FMO2, CYP4F22 | 0.029370911 |
| GO:0042581 | specific granule | 2 | CRISP3, LTF | 0.03923172 |
| GO:0031143 | pseudopodium | 2 | LDB3, MYOZ1 | 0.050995984 |
| GO:0031674 | I band | 2 | ATP2A1, MYZAP | 0.068377576 |
| GO:0016529 | sarcoplasmic reticulum | 2 | ATP2A1, S100A1 | 0.099435479 |
| Molecular function | ||||
| GO:0005506 | iron ion binding | 4 | CYP3A5, CYP4F22, LTF, ALOX12 | 0.012284039 |
| GO:0004497 | monooxygenase activity | 3 | CYP3A5, FMO2, CYP4F22 | 0.014289818 |
| GO:0008236 | serine-type peptidase activity | 3 | TMPRSS2, ENDOU, KLK12 | 0.016715968 |
| GO:0003779 | actin binding | 4 | XIRP2, SCIN, MYOZ1, TNNI1 | 0.056676048 |
KEGG Pathway of Validated Target Genes of miR-205-5p.
| KEGG ID | KEGG term | Counts(%) | Gene symbol | P |
|---|---|---|---|---|
| hsa00982 | Drug metabolism—cytochrome P450 | 4 | UGT1A7, CYP3A5, FMO2, ADH1B | 0.001081795 |
| hsa00830 | Retinol metabolism | 3 | UGT1A7, CYP3A5, ADH1B | 0.015969869 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3 | UGT1A7, CYP3A5, ADH1B | 0.021008586 |
| hsa05204 | Chemical carcinogenesis | 3 | UGT1A7, CYP3A5, ADH1B | 0.024310918 |
Figure 11.Gene Ontology (GO) analysis. A. biological process (BP); B. cellular componentry (CC), and C. molecular function (MF);
Figure 12.PPI network used to show bonds among target genes of miR-205-5p that are influence the dynamics the pathways of retinol metabolism, metabolism of xenobiotics by cytochrome P450, and chemical carcinogenesis. Nodes represent target genes of miR-205-5p and lines designate relationships between nodes.
Figure 13.Levels of expression of 4 target genes of miR-205-5p and measures of correlation with the drug metabolism-cytochrome P450 pathway. A.FMO2; B.ADH1B; C.UGT1A7; D.CYP3A5.
Figure 14.Spearman’s analysis of the correlation of the expression of miR-205-5p and the 4 target genes.